Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
Fredericks S et al. | Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. | 2006 | Transplantation | pmid:16969296 |
Rolles K et al. | A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. | 1999 | Transplantation | pmid:10551650 |
Lee D et al. | Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. | 2017 | Transplantation | pmid:27779572 |
Bayer ND et al. | Association of metabolic syndrome with development of new-onset diabetes after transplantation. | 2010 | Transplantation | pmid:20724958 |
Sakr M et al. | Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients. | 1992 | Transplantation | pmid:1373535 |
Koenen HJ et al. | Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. | 2003 | Transplantation | pmid:12792519 |
First MR | Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population. | 2001 | Transplantation | pmid:11585240 |
Tarumi K et al. | CTLA4IgG treatment induces long-term acceptance of rat small bowel allografts. | 1999 | Transplantation | pmid:10071020 |
Sokal EM et al. | Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. | 1997 | Transplantation | pmid:9392308 |
Heilman RL et al. | Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. | 2011 | Transplantation | pmid:21775930 |
Yamazaki S et al. | Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. | 2008 | Transplantation | pmid:18852671 |
Roth D et al. | Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. | 1998 | Transplantation | pmid:9458023 |
Chisholm MA et al. | Coadministration of tacrolimus with anti-acid drugs. | 2003 | Transplantation | pmid:12973105 |
Shapiro R et al. | A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. | 1999 | Transplantation | pmid:10030287 |
Kelly PA et al. | Ciprofloxacin does not block the antiproliferative effect of tacrolimus. | 1997 | Transplantation | pmid:9000686 |
Vafadari R et al. | Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. | 2012 | Transplantation | pmid:22960764 |
Raggi MC et al. | Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. | 2010 | Transplantation | pmid:21076373 |
Fuchinoue S et al. | Kidney transplantation after liver transplantation from the same donor: four cases of successful steroid withdrawal. | 2002 | Transplantation | pmid:11923698 |